In this study, we compared drug responses in AD between individuals with and without neuroinflammation-related conditions (e.g., AUD, epilepsy, HS, and TBI) in a quasi-difference-in-difference setting. We used a large-scale US nationwide health insurance claim data and covariate-adjusted Cox model to investigate frequent drugs. We identified drugs that might have potentially differential effects in AD in patients with neuroinflammation-related conditions compared to without.
